TBPH
Theravance Biopharma Inc

1,018
Mkt Cap
$892.34M
Volume
534,554.00
52W High
$20.33
52W Low
$7.90
PE Ratio
31.31
TBPH Fundamentals
Price
$17.68
Prev Close
$17.61
Open
$17.72
50D MA
$16.09
Beta
0.56
Avg. Volume
622,592.74
EPS (Annual)
-$1.16
P/B
3.83
Rev/Employee
$663,721.65
Loading...
Loading...
News
all
press releases
Hsbc Holdings PLC Takes Position in Theravance Biopharma, Inc. $TBPH
Hsbc Holdings PLC bought a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC...
MarketBeat·13h ago
News Placeholder
More News
News Placeholder
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1d ago
News Placeholder
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·3d ago
News Placeholder
Rhonda Farnum Sells 31,067 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock
Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction dated Wednesday, December 3rd. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares
Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday...
MarketBeat·6d ago
News Placeholder
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·6d ago
News Placeholder
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·6d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up Following Analyst Upgrade
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up Following Analyst Upgrade...
MarketBeat·14d ago
News Placeholder
Theravance Biopharma, Inc. $TBPH Shares Acquired by Jefferies Financial Group Inc.
Jefferies Financial Group Inc. grew its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 1,191.9% during the 2nd quarter, according to the company in its most recent disclosure with...
MarketBeat·14d ago

Latest TBPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.